Conv. Plasma
Nigella Sativa
Peg.. Lambda

All cetylpyridinium chloride..
Meta analysis
Home COVID-19 treatment researchCetylpyridinium ChlorideCetylpyridin.. (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Hospitalization 68% Improvement Relative Risk Viral clearance 83% Cetylpyridinium Chloride  Rengifo et al.  LATE TREATMENT  DB RCT Is late treatment with cetylpyridinium.. + chlorhexidine beneficial for COVID-19? Double-blind RCT 23 patients in Colombia (July - September 2020) Lower hospitalization (p=0.48) and improved viral clearance (p=0.056), not sig. Rengifo et al., Revista Estomatologia, May 2023 Favors cetylpyridinium chloride Favors control

A Mouthwash with Cetylpyridinium Chloride is reducing salivary SARS-CoV-2 viral load in +COVID-19

Rengifo et al., Revista Estomatologia, doi:10.25100/re.v31i1.12669, NCT04563689
May 2023  
  Source   PDF   All Studies   Meta AnalysisMeta
RCT 23 patients in Colombia, showing improved viral clearance with cetylpyridinium chloride plus chlorhexidine mouthwash.
Targeted administration to the respiratory tract provides treatment directly to the typical source of initial SARS-CoV-2 infection and replication, and allows for rapid onset of action, higher local drug concentration, and reduced systemic side effects (early treatment may be more beneficial).
risk of hospitalization, 67.6% lower, RR 0.32, p = 0.48, treatment 0 of 12 (0.0%), control 1 of 11 (9.1%), NNT 11, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of no viral clearance, 83.3% lower, RR 0.17, p = 0.06, treatment 1 of 12 (8.3%), control 5 of 10 (50.0%), NNT 2.4, day 5.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Rengifo et al., 22 May 2023, Double Blind Randomized Controlled Trial, placebo-controlled, Colombia, peer-reviewed, 13 authors, study period July 2020 - September 2020, this trial uses multiple treatments in the treatment arm (combined with chlorhexidine) - results of individual treatments may vary, trial NCT04563689 (history).
All Studies   All Outcomes   Submit Updates or Corrections
This PaperCetylpyridin..All
A Mouthwash with Cetylpyridinium Chloride is reducing salivary SARS-CoV-2 viral load in +COVID-19. Un enjuague con Cloruro de Cetilpiridinio redujo la carga salival del virus SARS CoV-2 en pacientes con Covid-19
Adolfo Contreras, Rubén León, Andrés Castillo, Vanessa Blanc Pociello, José Luis Bahamón, Yurani Giraldo, Hernando Espinoza, Gerardo Andrés Libreros-Zúñiga, Alejandro Contreras-Parra, Juan Gispert, | Julián Balanta-Melo, | Fausto, Andrés Alban, Beatriz Parra
Aim: The aim of this randomised, double-blind, placebo-controlled pilot clinical trial is to evaluate the capacity of a mouthwash to reduce SARS-CoV-2 viral load in the saliva of patients with COVID-19. Methods: Twenty-three symptomatic SARS-CoV-2-positive outpatients were selected and randomised into two groups and registered at NTC 04563689. Both groups rinsed and gargled for one minute with either distilled water (Placebo) or with 0.05% Cetylpyridinium chloride (CPC) plus 0.12% Chlorhexidine (CHX) mouthwash (PERIOAID Intensive Care  ). Saliva samples were collected before the use of placebo or mouthwash and after 15 minutes and 1 and 2 hours of either of the above treatment. A saliva sample was also taken five days after regular use of placebo or mouthwash twice daily. The virus was detected by qRT-PCR. Results: A great heterogeneity in the viral load values was observed at baseline in both groups for nasopharyngeal and saliva samples. Most of the patients who used the mouthwash (8/12) had a significant decrease in baseline viral load after 15 min (greater than 99% reduction). This inhibitory effect was maintained for up to two hours in 10 of the 12 patients. At five days, SARS-CoV-2 RNA was detected in only 1 patient from the mouthwash group and in 5 from the placebo group. Conclusions: This study points out that a CPC mouthwash can reduce the viral load in saliva of COVID-positive patients. This finding may be important in transmission control of SARS-CoV-2. Nevertheless, the clinical relevance of CPC mouthwash-reduction on SARS-CoV-2 shedding in saliva requires further study. KEY WORDS Antiviral mouthwash; SARS COV-2; Covid-19 patients; salivary viral load. RESMÚMEN Objetivo: El objetivo de este ensayo clínico piloto aleatorizado, doble ciego y controlado con placebo es evaluar la capacidad de un enjuague bucal para reducir la carga viral del SARS-CoV-2 en la saliva de pacientes con COVID-19. Materiales y métodos: Veintitrés pacientes ambulatorios positivos para SARS-CoV-2 sintomáticos fueron seleccionados y aleatorizados en dos grupos y registrados en el NTC 04563689. Ambos grupos se enjuagaron y hicieron gárgaras durante un minuto con agua destilada (placebo) o con cloruro de cetilpiridinio al 0 ,05 % (CPC). ) más enjuague bucal con Clorhexidina (CHX) al 0,12% (PERIOAID Intensive Care ). Se recolectaron muestras de saliva antes del uso de placebo o enjuague bucal y después de 15 minutos y 1 y 2 horas de cualquiera de los tratamientos anteriores. También se tomó una muestra de saliva cinco días después del uso regular de placebo o enjuague bucal dos veces al día. El virus fue detectado por qRT-PCR. Resultados: Se demostró una gran heterogeneidad en los valores de carga viral al inicio del estudio en grupos ambos para muestras de nasofaringe y saliva. La mayoría de los pacientes que usaron el enjuague bucal (8/12) tuvieron una disminución significativa en la carga viral inicial después de 15 minutos (reducción superior al 99 %). Este..
CONFLICT OF INTEREST Authors from Universidad del Valle and from ESE Centro do not have any interest conflict to declare however, the authors associated to Dentaid Research Centre worked within the company that provided the mouthwashes used in this study. SOURCE OF FUNDING The study was funded by investigators of Universidad del Valle, but mouthwashes and oral hygiene kits for patients were donated by Dentaid company.
Alexandersen, Chamings, Bhatta, SARS-CoV-2 genomic and subgenomic RNAs in diagnostic samples are not an indicator of active replication, Nat Commun, doi:10.1038/s41467-020-19883-7
Amirian, Potential fecal transmission of SARS-CoV-2: Current evidence and implications for public health, Int J Infect Dis, doi:10.1016/j.ijid.2020.04.057
Anderson, Sivalingam, Kang, Ananthanarayanan, Arumugam et al., Povidone-Iodine Demonstrates Rapid in vitro Virucidal Activity Against SARS-CoV-2, The Virus Causing COVID-19 Disease, Infect Dis Ther, doi:10.1007/s40121-020-00316-3
Bidra, Pelletier, Westover, Frank, Brown et al., Comparison of in vitro Inactivation of SARS CoV-2 with Hydrogen Peroxide and Povidone-Iodine Oral Antiseptic Rinses, J Prosthodont, doi:10.1111/jopr.13220
Burton, Clarkson, Goulao, Glenny, Mcbain et al., Antimicrobial mouthwashes (gargling) and nasal sprays administered to patients with suspected or confirmed COVID-19 infection to improve patient outcomes and to protect healthcare workers treating them, Cochrane Database Syst Rev
Chau, Lam, Dung, Yen, Minh et al., The natural history and transmission potential of asymptomatic SARS-CoV-2 infection, Clin Infect Dis
Davies, Buczkowski, Welch, Effective in vitro inactivation of SARS-CoV-2 by commercially available mouthwashes, J Gen Virol, doi:10.1099/jgv.0.001578
Ellinger, Bojkova, Zaliani, Cinati, Claussen et al., A SARS-CoV-2 cytopathicity dataset generated by high-content screening of a large drug repurposing collection, Sci Data, doi:10.1038/s41597-021-00848-4
Ferretti, Wymant, Kendall, Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing, Science, doi:10.1126/science.abb6936
Gottsauner, Michaelides, Schmidt, Scholz, Buchalla et al., A prospective clinical pilot study on the effects of a hydrogen peroxide mouthrinse on the intraoral viral load of SARS-CoV-2, Clin Oral Investig, doi:10.1007/s00784-020-03549-1
He, Zhao, Dong, Zhuang, Song et al., Effects of severe acute respiratory syndrome (SARS) coronavirus infection on peripheral blood lymphocytes and their subsets, Int J Infect Dis
Herrera, Serrano, Roldán, Sanz, Is the oral cavity relevant in SARS-CoV-2 pandemic?, Clin Oral Investig, doi:10.1007/s00784-020-03413-2
Huang, Li, Dunn, He, Taking account of asymptomatic infections: A modeling study of the COVID-19 outbreak on the Diamond Princess cruise ship, PLoS One, doi:10.1371/journal.pone.0248273
Jain, Grover, Singh, Sharma, Das et al., Chlorhexidine: An effective anticovid mouth rinse, J Indian Soc Periodontol, doi:10.4103/jisp.jisp_824_20
Koch-Heier, Hoffmann, Schindler, Lussi, Planz, Inactivation of SARS-CoV-2 through Treatment with the Mouth Rinsing Solutions ViruProX® and BacterX® Pro, Microorganisms
Komine, Yamaguchi, Okamoto, Yamamoto, Virucidal activity of oral care products against SARS-CoV-2 in vitro, J Oral Maxillofac Surg Med Pathol, doi:10.1016/j.ajoms.2021.02.002
Lu, Wang, Sakthivel, Whitaker, Murray et al., Randomized, double-blind, placebo-controlled clinical trial to assess the safety and effectiveness of a novel dual-action oral topical formulation against upper respiratory infections, BMC Infect Dis, doi:10.1186/s12879-016-2177-8
Martínez-Lamas, Diz, Pérez, Campo, Cabrera et al., Is povidone iodine mouthwash effective against SARS-CoV-2? First in vivo tests, Oral Dis, doi:10.1111/odi.13526
Meister, Brüggemann, Todt, Conzelmann, Müller et al., Virucidal Efficacy of Different Oral Rinses Against Severe Acute Respiratory Syndrome Coronavirus 2, J Infect Dis, doi:10.1093/infdis/jiaa471
O'donnell, Thomas, Stanton, Maillard, Murphy et al., Potential Role of Oral Rinses Targeting the Viral Lipid Envelope in SARS-CoV-2 Infection. Function (Oxf), doi:10.1093/function/zqaa002
Popkin, Zilka, Dimaano, Fujioka, Rackley et al., Cetylpyridinium Chloride (CPC) Exhibits Potent, Rapid Activity Against Influenza Viruses in vitro and in vivo, Pathog Immun, doi:10.20411/pai.v2i2.200
Seneviratne, Balan, Ko, Udawatte, Lai et al., Efficacy of commercial mouth-rinses on SARS-CoV-2 viral load in saliva: randomized control trial in Singapore, Infection, doi:10.1007/s15010-020-01563-9
Shen, Niu, Wang, Huang, Wang et al., High-Throughput Screening and Identification of Potent Broad-Spectrum Inhibitors of Coronaviruses, J Virol, doi:10.1128/JVI.00023-19
To, Tsang, Yip, Chan, Wu et al., Consistent detection of 2019 novel coronavirus in saliva, Clin Infect Dis, doi:10.1093/cid/ciaa149
Walsh, Jordan, Clyne, Rohde, Drummond et al., SARS-CoV-2 detection, viral load and infectivity over the course of an infection, J Infect, doi:10.1016/j.jinf.2020.06.067
Wang, Li, Guo, Zhen, Kong et al., Concentration and detection of SARS coronavirus in sewage from Xiao Tang Shan Hospital and the 309th Hospital of the Chinese People's Liberation Army, Water Sci Technol, doi:10.2166/wst.2005.0266
Who, Coronavirus disease (COVID-19) situation reports
Wölfel, Corman, Guggemos, Seilmaier, Zange et al., Virological assessment of hospitalized patients with COVID-2019, Nature, doi:10.1038/s41586-020-2196-x
Zhu, Guo, Xu, Chen, Viral dynamics of SARS-CoV-2 in saliva from infected patients, J Infect, doi:10.1016/j.jinf.2020.06.059
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop